Strides Pharma completes sale of majority stake in Pivot Path for about Rs 1,000 mn

Core Business DivestedStrategic Transactions View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹1125.60

prior close

₹1120.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.2%-0.5% vs market

Pharmaceuticals peers, median of 164sector-0.5%+0.2% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.1

15m

+1.4

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3+0.2-0.5-0.5+0.2

Next day

+0.6-0.5+1.1-0.7+1.3

-4.1-2.5-1.6-1.7-2.4

-4.8-0.6-4.1-1.2-3.5

-3.8+0.7-4.5-0.4-3.4

-4.6+0.9-5.5+0.3-4.9

-5.8+0.5-6.3+0.5-6.3

15d

-7.3-0.2-7.0-1.4-5.9

-11.2+2.9-14.1-1.4-9.8

+4.0+5.0-1.0+1.2+2.8

-3.3+3.7-7.0+0.6-3.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Strides Pharma Science has completed the sale of its majority stake in Pivot Path to a consortium led by Ascent Capital, with co-investor Vintage Classic, for an aggregate consideration of about Rs 1,000 million. The company has already received Rs 750 million, with the balance Rs 250 million payable on the first anniversary of the closing date. Consequently, Pivot Path has ceased to be a wholly owned subsidiary and will now be classified as an associate company, effective July 1, 2026.

Likely market impact

Divestment unlocks about Rs 1,000 mn cash for Strides (Rs 750 mn now, Rs 250 mn later). Pivot Path becomes an associate, reducing consolidated revenue.